Phase 3 N=353 BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
COVID-19
Primary: Number of Participants With an Ordinal Outcome on Day 5 — 1; 1; 4; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=126 Short and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis
Insomnia · End Stage Renal Disease
Primary: Insomnia Severity Index (ISI) Short-term — 12.47; 11.97; 13.05 score on a scale — p=0.6761
N/A N=35 PrEP Communication Intervention for Female Clients of a Needle Exchange
HIV/AIDS
Primary: Change in PrEP Uptake and Adherence — 0; 1; 2; 3 Participants
N/A N=47 The Accuracy of Smartphone Pulse Oximetry in Patients Visiting an Outpatient Pulmonary Function Lab for a 6-Minute Walk Test
Oximetry
Primary: Accuracy of Smartphone Pulse Oximeters — 98 percentage of oxygen saturation
Phase 3 N=24 Suppressive Antibacterial Therapy With Once-Weekly Secnidazole Granules to Prevent Recurrent Bacterial Vaginosis; A Pilot Study
Recurrent Bacterial Vaginosis
Primary: Number of Subjects With at Least One Episode of Bacterial Vaginosis — 8 Participants
Phase 2 N=222 Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme
Glioblastoma Multiforme
Primary: Objective Response Rate (ORR) — 17.6; 27.0; 8.8; 8.3 percentage of participants
Phase 2 N=27 Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc)
Diffuse Cutaneous Systemic Sclerosis
Primary: Number of Participants With at Least One Adverse Event (AE) for IgPro20 — 9; 9 Participants
Phase 1 N=55 Bioequivalence Study of Esomeprazole 20 Milligram (mg) Delayed-Release Capsules in Healthy Adult Participants
Gastrointestinal Diseases
Primary: Maximum Observed Post Dose Concentration (Cmax) — 483; 514 Nanograms per milliliter
Phase 2 N=62 Pharmacological Modulation of Hippocampal Activity in Psychosis 2
Schizophrenia; Psychosis
Primary: Hippocampal Activity (Arterial Spin Labeling [ASL] Study) After Levetiracetam (LEV) — 28.3; 27.1; 28.0; 28.5 ml/100g/min
N/A N=199 Comparison of Two Intrauterine Devices (IUDs) Among Cape Town HIV-positive Women
HIV
Primary: Participants With Detectable Genital Tract HIV Ribonucleic Acid (RNA) Viral Load (VL) — 18; 23; 10; 7 Participants — p=0.66
N/A N=472 Family Obesity Intervention: Motivational Interviewing and Community Support
Obesity
Primary: Change in Adult Body Mass Index — 0.3; -0.1 kg/m2 — p=0.67
N/A N=141 PORTuguese Research on Telemonitoring With CareLink® (PORTLink)
Arrhythmia
Primary: Number of Patient Satisfied or Very Satisfied With Carelink — 34; 34 Participants
Phase 3 N=449 A Study to Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Neovascular Age-related Macular Degeneration
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) — 6.7; 6.6 letters
Phase 1 N=29 A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer
Non-small Cell Lung Cancer
Primary: Phase 1a: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0 Participants
Phase 1 N=16 A Study of Single and Multiple Doses of ALXN1210 in Healthy, Adult Japanese Participants
Healthy
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 2; 3; 8 Participants